SM1
MCID: SCH060
MIFTS: 40

Schistosoma Mansoni Infection, Susceptibility/ (SM1)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Schistosoma Mansoni Infection, Susceptibility/

MalaCards integrated aliases for Schistosoma Mansoni Infection, Susceptibility/:

Name: Schistosoma Mansoni Infection, Susceptibility/ 57
Schistosoma Mansoni Infection, Susceptibility/resistance to 57 13
Schistosomiasis 59 72
Sm1 57 17
Schistosoma Mansoni, Intensity of Infection by; Sm1 57
Schistosoma Mansoni, Intensity of Infection by 57
Bilharziasis 59

Characteristics:

Orphanet epidemiological data:

59
schistosomiasis
Inheritance: Not applicable; Age of onset: All ages;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
schistosoma mansoni infection, susceptibility/:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

OMIM 57 181460
MESH via Orphanet 45 D012552
ICD10 via Orphanet 34 B65.0 B65.1 B65.2 more
UMLS via Orphanet 73 C0036323
Orphanet 59 ORPHA1247
MedGen 42 C1866993
UMLS 72 C0036323

Summaries for Schistosoma Mansoni Infection, Susceptibility/

MalaCards based summary : Schistosoma Mansoni Infection, Susceptibility/, also known as schistosoma mansoni infection, susceptibility/resistance to, is related to intestinal schistosomiasis and urinary schistosomiasis. An important gene associated with Schistosoma Mansoni Infection, Susceptibility/ is SM1 (Schistosoma Mansoni, Susceptibility/Resistance To). The drugs Lumefantrine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotype is abnormality of the immune system.

More information from OMIM: 181460

Related Diseases for Schistosoma Mansoni Infection, Susceptibility/

Diseases related to Schistosoma Mansoni Infection, Susceptibility/ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 581)
# Related Disease Score Top Affiliating Genes
1 intestinal schistosomiasis 12.9
2 urinary schistosomiasis 12.8
3 pulmonary arterial hypertension associated with schistosomiasis 12.4
4 cercarial dermatitis 12.2
5 neuroschistosomiasis 11.7
6 hepatic fibrosis, severe due to schistosoma mansoni infection 11.2
7 portal hypertension 10.9
8 splenomegaly 10.8
9 varicose veins 10.7
10 bladder cancer 10.7
11 hypereosinophilic syndrome 10.6
12 parasitic helminthiasis infectious disease 10.6
13 liver cirrhosis 10.6
14 fibrosis of extraocular muscles, congenital, 1 10.6
15 esophageal varix 10.6
16 pulmonary hypertension 10.5
17 allergic hypersensitivity disease 10.5
18 diarrhea 10.5
19 filariasis 10.5
20 liver disease 10.5
21 malaria 10.4
22 hepatitis b 10.4
23 appendicitis 10.4
24 fascioliasis 10.4
25 hepatitis c 10.4
26 small cell carcinoma 10.4
27 paragonimiasis 10.4
28 myelitis 10.4
29 infertility 10.4
30 viral hepatitis 10.4
31 pulmonary hypertension, primary, 1 10.3
32 ancylostomiasis 10.3
33 hepatitis 10.3
34 cytokine deficiency 10.3
35 filarial elephantiasis 10.3
36 clonorchiasis 10.3
37 onchocerciasis 10.3
38 glomerulonephritis 10.3
39 urinary tract obstruction 10.3
40 transverse myelitis 10.3
41 hepatocellular carcinoma 10.3
42 cystitis 10.3
43 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
44 hydronephrosis 10.3
45 hepatitis c virus 10.3
46 salmonellosis 10.3
47 hypersplenism 10.3
48 kala-azar 1 10.3
49 ectopic pregnancy 10.3
50 leishmaniasis 10.3

Graphical network of the top 20 diseases related to Schistosoma Mansoni Infection, Susceptibility/:



Diseases related to Schistosoma Mansoni Infection, Susceptibility/

Symptoms & Phenotypes for Schistosoma Mansoni Infection, Susceptibility/

Human phenotypes related to Schistosoma Mansoni Infection, Susceptibility/:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the immune system 32 HP:0002715

Symptoms via clinical synopsis from OMIM:

57
Immunology:
schistosoma mansoni infection susceptibility/resistance

Clinical features from OMIM:

181460

Drugs & Therapeutics for Schistosoma Mansoni Infection, Susceptibility/

Drugs for Schistosoma Mansoni Infection, Susceptibility/ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lumefantrine Approved Phase 4 82186-77-4 6437380
2
Artemether Approved Phase 4 71963-77-4 68911 119380
3 Artemether, Lumefantrine Drug Combination Phase 4
4
Myrrh Approved Phase 3 9000-45-7
5
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
6
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
7
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
8
leucovorin Approved Phase 3 58-05-9 143 6006
9
Triclabendazole Approved, Investigational Phase 3 68786-66-3
10
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
11
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
12
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
13
Tranexamic Acid Approved Phase 3 1197-18-8 5526
14
Mefloquine Approved, Investigational Phase 3 53230-10-7 4046
15
Artesunate Approved, Investigational Phase 3 88495-63-0 5464098 6917864
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
17
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483
18
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
19 Iron Supplement Phase 3
20 Hematinics Phase 3
21 Ferric Compounds Phase 3
22 Fanasil, pyrimethamine drug combination Phase 3
23 Micronutrients Phase 2, Phase 3
24 Trace Elements Phase 2, Phase 3
25 Tubulin Modulators Phase 3
26 Antimitotic Agents Phase 3
27 Folic Acid Antagonists Phase 3
28 Renal Agents Phase 3
29 Sulfalene Phase 3
30 Vitamin B9 Phase 3
31 Vitamin B Complex Phase 3
32 Folate Phase 3
33 Anti-Infective Agents, Urinary Phase 3
34 Nutrients Phase 2, Phase 3
35 Dermatologic Agents Phase 2, Phase 3
36 Astringents Phase 2, Phase 3
37 Artemisinins Phase 3
38 Artemisinine Phase 3
39 Hemostatics Phase 3
40 Coagulants Phase 3
41 Antifibrinolytic Agents Phase 3
42 Antimalarials Phase 3
43 Antiprotozoal Agents Phase 3
44 Antiviral Agents Phase 3
45
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
46
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
47
Indian frankincense Approved, Experimental, Investigational Phase 1, Phase 2
48
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
49
Calcium Approved, Nutraceutical Phase 1, Phase 2 7440-70-2 271
50
Imidazole Experimental, Investigational Phase 1, Phase 2 288-32-4 795

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
5 Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial Unknown status NCT03133832 Phase 3 Companion Tablet
6 Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Unknown status NCT02541708 Phase 3 Ferric carboxymaltose;Ferrous sulfate + folic acid
7 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire Completed NCT02868385 Phase 3 4x Praziquantel;1x Praziquantel
8 Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study Completed NCT01529710 Phase 3 Myrrh
9 Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel Completed NCT01558336 Phase 3 praziquantel
10 Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children Completed NCT00870649 Phase 3
11 Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children Completed NCT01054651 Phase 3 Artesunate+Sulfamethoxypyrazine/pyrimethamine;Praziquantel
12 Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
13 A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya. Completed NCT01166815 Phase 2, Phase 3
14 Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon Recruiting NCT03779347 Phase 3 Praziquantel
15 Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial Recruiting NCT03640403 Phase 3 Dihydroartemisinin-piperaquine;Artesunate-amodiaquine
16 Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial Recruiting NCT01658124 Phase 3 Tranexamic Acid;Placebo
17 An Open Label, Phase III Efficacy and Safety Study of L Praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®) Not yet recruiting NCT03845140 Phase 3 L-PZQ ODT;Biltricide®;L-PZQ ODT
18 A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children Not yet recruiting NCT03893097 Phase 3 Praziquantel;Artesunate + Mefloquine
19 Safety and Efficacy of a Novel Candidate Peptide Vaccine Against HCV Infection in Healthy Volunteers and in Treated (Non-responders/ Responders) Chronic HCV Patients. Clinical Trials Phases I and II Unknown status NCT01718834 Phase 1, Phase 2
20 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
21 Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines. Completed NCT01901484 Phase 2 Praziquantel
22 Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2) Completed NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
23 S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) Completed NCT00486863 Phase 2 Praziquantel
24 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial Completed NCT03041766 Phase 2 GLA-SE solution
25 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial Active, not recruiting NCT03799510 Phase 2 GLA-SE solution
26 Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four Not yet recruiting NCT03640377 Phase 2 Praziquantel
27 A Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of the Sm-TSP-2/Alhydrogel® Schistosomiasis Vaccine in Healthy Exposed Ugandan Adults Not yet recruiting NCT03910972 Phase 1, Phase 2
28 Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial Not yet recruiting NCT03924596 Phase 1, Phase 2 AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid);Potassium Sodium Hydrogen Citrate
29 Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis Completed NCT01512277 Phase 1
30 Praziquantel Pharmacokinetics in Pregnancy and During Lactation Completed NCT01288872 Phase 1 Praziquantel
31 Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
32 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1
33 Group A Streptococcal Human Challenge Study: Building a Pharyngitis Model to Accelerate Vaccine Development Recruiting NCT03361163 Phase 1
34 A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Active, not recruiting NCT03110757 Phase 1
35 Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas Unknown status NCT03158298
36 Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. Unknown status NCT01260012
37 Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial Unknown status NCT01869465
38 The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study) Unknown status NCT02329314
39 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
40 ANRS 12320 IMMHoTHep : Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C Unknown status NCT02826447
41 Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding Completed NCT02755324
42 Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status Completed NCT01553552
43 Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children Completed NCT02144389 Praziquantel (PZQ)
44 Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment Completed NCT00414479 praziquantl, iron, ACT
45 Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya Completed NCT00463307
46 Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Completed NCT00276224 ferrous sulphate (drug)
47 Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Completed NCT00463632
48 Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Completed NCT00463593
49 Women and Childres at the Focal Point for the Schistosomiasis Control and Sustainability and Effectiveness in the Hydro Agricultural Zone of Sourou, Burkina Faso Completed NCT00463528
50 Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Completed NCT01424410

Search NIH Clinical Center for Schistosoma Mansoni Infection, Susceptibility/

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Praziquantel

Genetic Tests for Schistosoma Mansoni Infection, Susceptibility/

Anatomical Context for Schistosoma Mansoni Infection, Susceptibility/

MalaCards organs/tissues related to Schistosoma Mansoni Infection, Susceptibility/:

41
Liver, Testes, T Cells, Colon, Spinal Cord, Spleen, Skin

Publications for Schistosoma Mansoni Infection, Susceptibility/

Articles related to Schistosoma Mansoni Infection, Susceptibility/:

(show top 50) (show all 15699)
# Title Authors PMID Year
1
Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. 38 8
10441577 1999
2
Absence of linkage between MHC and a gene involved in susceptibility to human schistosomiasis. 38 8
9698772 1998
3
Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. 38 8
8841190 1996
4
Evidence for the segregation of a major gene in human susceptibility/resistance to infection by Schistosoma mansoni. 38 8
1902058 1991
5
Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. 8
21059925 2010
6
Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity. 8
16301741 2005
7
Full results of the genome-wide scan which localises a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. 8
10094195 1999
8
Further evidence suggesting the presence of a locus, on human chromosome 5q31-q33, influencing the intensity of infection with Schistosoma mansoni. 8
9311752 1997
9
Label-free nanostructured biosensor for Schistosoma mansoni detection in complex biological fluids. 38
31357311 2019
10
Maternal anemia type during pregnancy is associated with anemia risk among offspring during infancy. 38
31129681 2019
11
Effect of nanoparticles on the therapeutic efficacy of praziquantel against Schistosoma mansoni infection in murine models. 38
31406407 2019
12
Suitability of commercially available POC-CCA tests for schistosomiasis: Considerations for efficiency, reproducibility and decision making criteria for field application in areas of low endemicity. 38
31194970 2019
13
Population genetics of Oncomelania hupensis snails, intermediate hosts of Schistosoma japonium, from emerging, re-emerging or established habitats within China. 38
31173738 2019
14
A retrospective study of schistosomiasis-associated pulmonary hypertension from an endemic area in Brazil. 38
31334331 2019
15
Schistosoma japonicum cathepsin B as potential diagnostic antigen for Asian zoonotic schistosomiasis. 38
31377909 2019
16
Medical care for migrant children in Europe: a practical recommendation for first and follow-up appointments. 38
31240389 2019
17
An immunohistochemical analysis of peptidergic neurons apparently associated with reproduction and growth in Biomphalaria alexandrina. 38
30923005 2019
18
Does physical exercise influence in the development of neuroeschistosomiasis? 38
31377443 2019
19
Th2 CD4+ T Cells Are Necessary and Sufficient for Schistosoma-Pulmonary Hypertension. 38
31339057 2019
20
Detection of canine Schistosoma japonicum infection using recombinant thioredoxin peroxidase-1 and tandem repeat proteins. 38
31391359 2019
21
Simultaneous colonization by Escherichia coli and Klebsiella pneumoniae harboring mcr-1 in Brazil. 38
31025216 2019
22
The Elimination of Neglected Tropical Diseases (NTDs): A Case Study Exemplifying How Foreign Assistance Funding Can Be Catalytic in Reducing the Burden of Major Global Health Conditions. 38
31402376 2019
23
Activation of the NLRP3 and AIM2 inflammasomes in a mouse model of Schistosoma mansoni infection. 38
31412958 2019
24
IL-9 blockage reduces early hepatic granuloma formation and fibrosis during Schistosoma japonicum infection in mice. 38
31436861 2019
25
An improved genome assembly of the fluke Schistosoma japonicum. 38
31390359 2019
26
Is there a gap between health education content and practice toward schistosomiasis prevention among schoolchildren along the shores of Lake Victoria in Kenya? 38
31425499 2019
27
An innovative and user-friendly scoring system for standardised quantitative interpretation of the urine-based point-of-care strip test (POC-CCA) for the diagnosis of intestinal schistosomiasis- a proof-of-concept study. 38
31425672 2019
28
Five-Year Impact of Different Multi-Year Mass Drug Administration Strategies on Childhood Schistosoma mansoni-Associated Morbidity: A Combined Analysis from the Schistosomiasis Consortium for Operational Research and Evaluation Cohort Studies in the Lake Victoria Regions of Kenya and Tanzania. 38
31407653 2019
29
Urogenital Schistosomiasis and Sexually Transmitted Coinfections among Pregnant Women in a Schistosome-Endemic Region of the Democratic Republic of Congo. 38
31392943 2019
30
A rapid diagnostic multiplex PCR approach for xenomonitoring of human and animal schistosomiasis in a 'One Health' context. 38
31369105 2019
31
Evaluation of integrated interventions layered on mass drug administration for urogenital schistosomiasis elimination: a cluster-randomised trial. 38
31255591 2019
32
Inflammation-associated pathologies in a case of prostate schistosomiasis: Implications for a causal role in prostate carcinogenesis. 38
31212384 2019
33
The prevalence of schistosomiasis in Uganda: A nationally representative population estimate to inform control programs and water and sanitation interventions. 38
31412023 2019
34
Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis. 38
31370708 2019
35
Integration of schistosomiasis control activities within the primary health care system: a critical review. 38
31391100 2019
36
Pulmonary Hypertension as a Primary Presentation for Schistosomiasis, a Case Report of Unusual Presentation. 38
31398724 2019
37
Participatory integrated control strategies and elimination of schistosomiasis in sub-Saharan Africa. 38
31255590 2019
38
A comparative in silico analysis of Rab5 proteins from pathogenic species to find its role in the pathogenesis. 38
31432591 2019
39
Separation of praziquantel enantiomers using simulated moving bed chromatographic unit with performance designed for semipreparative applications. 38
31185131 2019
40
Long-term ethanol intake causes morphological changes in Schistosoma mansoni adult worms in mice. 38
31150655 2019
41
The Proteasome as a Drug Target in the Metazoan Pathogen, Schistosoma mansoni. 38
31355632 2019
42
Toxicological effects of Ramalina aspera (lichen) on Biomphalaria glabrata snails and Schistosoma mansoni cercariae. 38
31082366 2019
43
Wuchereria bancrofti infection is linked to systemic activation of CD4 and CD8 T cells. 38
31425508 2019
44
Praziquantel Ameliorates CCl4 -induced Liver Fibrosis in Mice by Inhibiting TGF-β/Smad Signalling via Upregulating Smad7 in Hepatic Stellate Cells. 38
31412137 2019
45
Cerebral schistosomiasis: Case series from Qatar. 38
31295550 2019
46
Concomitant classic Hodgkin lymphoma and schistosomiasis. 38
30328130 2019
47
State and parameter estimation for a class of schistosomiasis models. 38
31288033 2019
48
Macrophages assemble! But do they need IL-4R during schistosomiasis? 38
31267552 2019
49
Population Structure and Dynamics of Helminthic Infection: Schistosomiasis. 38
31325285 2019
50
Molecular characterization and functional analysis of the Schistosoma mekongi Ca2+-dependent cysteine protease (calpain). 38
31362766 2019

Variations for Schistosoma Mansoni Infection, Susceptibility/

Expression for Schistosoma Mansoni Infection, Susceptibility/

Search GEO for disease gene expression data for Schistosoma Mansoni Infection, Susceptibility/.

Pathways for Schistosoma Mansoni Infection, Susceptibility/

GO Terms for Schistosoma Mansoni Infection, Susceptibility/

Sources for Schistosoma Mansoni Infection, Susceptibility/

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....